HLA-B*5801 gene carrying rate and laboratory testing indicators in patients with gouty arthritis

doi:10.3969/j.issn.1673-8640.2021.09.002

Abstract

Abstract:

Objective To investigate the correlation of HLA-B*5801 gene carrying status and laboratory testing indicators in patients with gouty arthritis（GA）. Methods Totally,120 GA patients were enrolled to determine HLA-B*5801 genotype,uric acid（UA）,alanine aminotransferase（ALT）,alkaline phosphatase（ALP）,C-reactive protein（CRP）,the percentage of neutrophil,the percentage of lymphocyte,the percentage of eosinophil（EO%）,mean platelet volume（MPV） and erythrocyte sedimentation rate（ESR）,and the neutrophil/lymphocyte ratio（NLR） and ALT/ALP ratio were calculated. A total of 50 healthy subjects were enrolled as healthy control group. According to the levels of UA,120 GA patients were classified into low-level UA（UA<420 μmol/L） group,medium-level UA（UA 420-600 μmol/L） group and high-level UA（UA>600 μmol/L） group. The correlation between laboratory testing indicators with UA was evaluated by Correl analysis. Results Among the 120 patients,35（29.2%） cases carried HLA-B *5801 gene,the UA,NLR,EO%,CRP,ESR and ALT/ALP ratio in GA group were higher than those in healthy control group（P<0.05）,and MPV was lower（P<0.05）. Compared with HLA-B*5801 gene carrying group,EO% and MPV were higher than those in non-carrying group（P<0.05）,while UA was lower than that in non-carrying group（P<0.05）,and NLR,CRP,ESR,ALT/ALP ratio had no statistical significance（P>0.05）. ALT/ALP ratios were increased in turn among low-level,medium-level and high-level UA groups（P<0.05）. EO% in medium-level UA group was lower than that in high-level UA group（P<0.05）,and NLR and ESR were higher than those in high-level UA group and low-level UA group（P<0.05）. MPV and CRP had no statistical significance among the 3 groups（P>0.05）. NLR,ESR and ALT/ALP ratio were positively correlated with UA（r values were 0.959,0.953 and 0.994,respectively,P<0.05）,while MPV was negatively correlated with UA（r=-0.998,P<0.05）. There was no correlation between EO%,CRP and UA（r values were 0.647 and 0.091,respectively,P>0.05）. Conclusions The gene carrying rate of HLA-B*5801 gene in patients with GA is high. The determination of HLA-B*5801 gene and related laboratory testing indicators will be helpful to comprehensively evaluate the disease status of patients.

Key words: HLA-B*5801 genotype, Gouty arthritis, Laboratory testing indicator

CLC Number:

R446.7

FANG Zhongjun, JI Weiqing, ZHANG Jingxian, WU Jintao, WU Weihua, JIANG Ying, HAN Zhenge, HE Dongyi, BIAN Yanqin, SHEN Yu, XIAO Lianbo, XIE Donghao, SUN Yang. HLA-B*5801 gene carrying rate and laboratory testing indicators in patients with gouty arthritis[J]. Laboratory Medicine, 2021, 36(9): 896-900.

Figures/Tables 4

References 17

[1]	李迎春, 徐建华. 急性痛风性关节炎的发病机制及研究进展[J]. 安徽医学, 2013, 34(1):96-98.
[2]	杨青, 童德银, 金鑫, 等. 别嘌醇致严重皮肤不良反应与HLA-B*58∶01等位基因相关性的研究进展[J]. 药物不良反应杂志, 2018, 20(1):43-47.
[3]	JARJOUR S, BARRETTE M, NORMAND V, et al. Genetic markers associated with cutaneous adverse drug reactions to allopurinol:a systematic review[J]. Pharmacogenomics, 2015, 16(7):755-767. DOI URL
[4]	NEOGI T, JANSEN T L, DALBETH N, et al. 2015 Gout classification criteria:an American College of Rheumatology/European League Against Rheumatism collaborative initiative[J]. Ann Rheum Dis, 2015, 74(10):1789-1798. DOI URL
[5]	刘威, 黎颖然, 张文渊, 等. 中国汉族人群HLA-B*58:01等位基因与别嘌醇引起严重皮肤不良反应关联性的Meta分析[J]. 今日药学, 2019, 29(3):177-181.
[6]	云雄, 吴丹娜, 韩方璇, 等. 海南省汉族人群HLA-B*5801基因多态性与别嘌醇所致不良反应的相关性研究[J]. 中国药房, 2018, 29(9):1256-1259.
[7]	ILLING P T, VIVIAN J P, DUDEK N L, et al. Immune self-reactivity triggered by drug-modified HLA-peptide repertoire[J]. Nature, 2012, 486(7404):554-558. DOI URL
[8]	李康, 胡伟新. HLA-B*5801基因型与别嘌呤醇过敏反应[J]. 肾脏病与透析肾移植杂志, 2014, 23(6):553-558.
[9]	JUTKOWITZ E, DUBREUIL M, LU N, et al. The cost-effectiveness of HLA-B*5801 screening to guide initial urate-lowering therapy for gout in the united states[J]. Semin Arthritis Rheum, 2017, 46(5):594-600. DOI URL
[10]	赵丽珂, 周荣伟, 程永静, 等. 痛风和高尿酸血症患者携带HLA-B*5801及伴发疾病的比较[J]. 新医学, 2017, 48(6):385-389.
[11]	王静, 郑群, 金霞霞, 等. RDW与NLR联合检测在强直性脊柱炎中的临床意义[J]. 检验医学, 2019, 34(8):704-709.
[12]	庞雨冰, 周玮, 刘家欢, 等. 中性粒细胞/淋巴细胞与血小板/淋巴细胞比值对痛风疾病活动及治疗后病情的评估[J]. 实用医学杂志, 2018, 34(20):3441-3444.
[13]	HSIEH C Y, LI L H, RAO Y K, et al. Mechanistic insight into the attenuation of gouty inflammation by Taiwanese green propolis via inhibition of the NLRP3 inflammasome[J]. J Cell Physiol, 2019, 234(4):4081-4094. DOI URL
[14]	赖爱云, 徐健, 陶丽. 肿瘤坏死因子-α在痛风性关节炎患者炎症反应中的作用[J]. 中国临床研究, 2018, 31(9):1165-1169.
[15]	李影, 陆家睛, 陈福娟, 等. 嗜酸性皮病临床研究进展[J]. 现代中西医结合杂志, 2019, 28(15):1701-1703.
[16]	徐燕群, 韦蓉梅, 吴红慧. 膝骨性关节炎与C反应蛋白和血沉的相关性[J]. 现代诊断与治疗, 2019, 30(12):2071-2072.
[17]	苏柯, 李龙杰, 王军. 血小板平均体积与膝骨关节炎伴滑膜炎的相关性研究[J]. 实用骨科杂志, 2016, 22(8):701-703.

性别	HLA-B*5801基因型		合计
性别	携带	未携带	合计
男性	29	77	106
女性	6	8	14
合计	35	85	120

性别	HLA-B*5801基因型		合计
性别	携带	未携带	合计
男性	29	77	106
女性	6	8	14
合计	35	85	120

组别	例数	UA/（μmol/L）	NLR	EO%/%
GA组	120	504.80±151.70^*	3.22±2.17^*	1.65（0.90~2.78）
正常对照组	50	287.00±45.80	1.98±0.65	1.70（1.20~2.40）
组别	MPV/fL	CRP/（mg/L）	ESR/（mm/h）	ALT/ALP比值
GA组	10.19±1.00^*	4.96（1.62~21.50）^*	10.50（4.00~30.75）^*	0.53±0.38^*
正常对照组	10.62±0.77	1.10（0.70~1.70）	3.00（2.00~6.00）	0.21±0.05

组别	例数	UA/（μmol/L）	NLR	EO%/%
GA组	120	504.80±151.70^*	3.22±2.17^*	1.65（0.90~2.78）
正常对照组	50	287.00±45.80	1.98±0.65	1.70（1.20~2.40）
组别	MPV/fL	CRP/（mg/L）	ESR/（mm/h）	ALT/ALP比值
GA组	10.19±1.00^*	4.96（1.62~21.50）^*	10.50（4.00~30.75）^*	0.53±0.38^*
正常对照组	10.62±0.77	1.10（0.70~1.70）	3.00（2.00~6.00）	0.21±0.05

组别	例数	UA/（μmol/L）	NLR	EO%/%
携带组	35	494.5±145.9^*	3.23±2.13	2.30（1.40~3.10）^*
未携带组	85	555.1±163.4	3.45±2.29	1.50（0.83~2.30）
组别	MPV/fL	CRP/（mg/L）	ESR/（mm/h）	ALT/ALP比值
携带组	10.30±0.99^*	10.00（3.15~22.65）	11.00（5.00~28.50）	0.45（0.22~0.63）
未携带组	9.96±1.01	3.55（1.50~18.83）	9.50（4.00~33.25）	0.48（0.24~0.66）